Sun Pharma to buy US drugmaker Organon in $11.75 Billion All-Cash Deal
The deal gives Sun Pharma full ownership of Organon and would create a top-25 global drugmaker with $12.4 billion in combined revenue, the companies said.
- On Sunday, Sun Pharmaceutical Industries Limited announced a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, or $14.00 per share.
- Sun Pharma Executive Chairman Dilip Shanghvi said the transaction represents a 'significant opportunity' to build on the company's vision, noting Organon's portfolio and global reach are 'highly complementary' to Sun Pharma's existing business.
- Upon closing, the combined entity expects to rank among the top 25 global pharmaceutical companies with $12.4 billion in revenue, maintaining a presence in 150 countries with 27% revenue share in innovative medicines.
- Following a comprehensive review of strategic alternatives, Organon Executive Chair Carrie Cox stated the board determined the deal offers 'compelling and immediate value' to stockholders, with both boards approving the transaction.
- The transaction is expected to close in early 2027, subject to customary conditions including regulatory approvals and stockholder voting; management cautioned that uncertainties could delay or prevent completion.
60 Articles
60 Articles
Organon, best known for its contraceptive pills, is coming under Indian ownership. Sun Pharma, India's largest pharmaceutical company, will be the new owner.
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal
Organon (NYSE:OGN), a women’s health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon in an all-cash deal. Trading volume reached 133.6 million shares, about 1,618% above its three-month average of 7.8 million shares. Organon went public via a spin-off from Merck in 2021 and has fallen 60% since going public.How the markets moved today…
Acquisition: Of all Indian pharmaceutical companies, Sun Pharma is perhaps the most shrewd. What started 43 years ago as a small drug dealer,…
NOS
Omroep BrabantSun Pharmaceutical is paying nearly 12 billion dollars for the originally Dutch company. It concerns one of the largest foreign acquisitions ever by an Indian company.
Indian Pharma Billionaire Dilip Shanghvi Doubles Down On The U.S. With $11.8 Billion Acquisition
With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the world’s top 25 drugmakers.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
